Das Risiko der Maculadegeneration wird in Abhängigkeit von der gerauchten Zigarettenmenge vervielfacht.
Auch Passivraucher haben ein erhöhtes Risiko, durch diese Augenerkrankung zu erblinden (siehe unten und
http://bjo.bmjjournals.com/cgi/content/abstract/90/1/75), PNAS 2005: Zur Pathogenese der Maculadegeneration

Endokrine Orbitopathie
: 70% der der Patienten sind Raucher. Die Anzahl der Zigaretten prognostiziert die Entstehung von Doppelbildern. Nach Tabakabstinenz kommt es zur Besserung der Symptome. Hypothesen:  Reizwirkung von Tabakrauch und Hypoxie im Retrobulbärraum (Symptome korrelieren mit Zytokinen).

Smoking and blindness (Editorial)

BMJ 2004;328:537-538 (6 March). http://bmj.bmjjournals.com/cgi/content/full/328/7439/537

Strong evidence for the link, but public awareness lags

While most people and many patients attending eye clinics recognise many adverse health hazards of tobacco smoking, they remain largely unaware of its link with blindness. Although smoking is associated with several eye diseases, including nuclear cataract (1,2) and thyroid eye disease (3), the most common cause of smoking related blindness is age related macular degeneration, which results in severe irreversible loss of central vision. Current treatment options are of only partial benefit to selected patients. Identifying modifiable risk factors to inform efforts for prevention is a priority.

A risk factor is generally judged to be a cause of disease if certain causality criteria are fulfilled (4). Applying commonly used criteria (4) to available evidence provides strong evidence of a causal link between tobacco smoking and age related macular degeneration. The strength of association is confirmed in a pooled analysis of data from three cross sectional studies, totalling 12 468 participants, in which current smokers had a significant threefold to fourfold increased age adjusted risk of age related macular degeneration compared with never smokers (1). By way of comparison, although
the relative risks associated with smoking for lung cancer and chronic obstructive pulmonary disease are in excess of 20, the relative risk for ischaemic heart disease in men is only 1.6 (5). Consistency of effect is demonstrated as smoking was the strongest environmental risk factor for age related macular degeneration across these three different study populations in Australia, North America, and Europe (2-4) A temporal relation between exposure and outcome was established through long term follow up in these cohorts (5-7). A dose-response relation between exposure to smoking and age related macular degeneration is demonstrated as the risk of early disease increases with number of pack years (6,7). Finally, this causal association is biologically plausible, as age related macular degeneration may reflect accumulated oxidative damage in the retina and smoking is known to impede the protective effects of antioxidants and to reduce macular pigment density (8).
Owen et al estimated 214 000 UK residents to have visual impairment (best visual acuity 6/18-3/60 Snellen) and 71 000 individuals to be blind (better eye visual acuity < 3/60 Snellen) because of age related macular degeneration (9). We estimate that 53 900 United Kingdom residents older than 69 years may have visual impairment because of age related macular degeneration attributable to smoking of whom 17 800 are blind (see table and methods on bmj.com, 1, 6, 9).

Randomised controlled trials examining whether smoking cessation interventions reduce incidence or progression of smoking related diseases are problematic. Observational studies show a protective effect of smoking cessation on the development of age related macular degeneration, as former smokers have an only slightly increased risk of age related macular degeneration compared with never smokers (1). The reversibility of this association in smokers with age related macular degeneration in one eye has important implications for prevention of late macular involvement in the second eye. In addition, continuing smoking is associated with poorer outcome after photocoagulation with argon laser (10). Continued smoking could perhaps also adversely affect the long term response to newer treatments such as photodynamic therapy.

Robust evidence indicates that smoking cessation support results in higher abstinence rates (8). Guidelines recommend that smokers are referred to professional smoking cessation services and should generally be offered nicotine replacement therapy.w8 Many diabetes, cardiac, and respiratory NHS clinics now incorporate smoking cessation support into their services and ophthalmology or optometry services could follow likewise. The acceptability
of this intervention among eye care personnel in the United States is high, but time and knowledge constraints may hinder implementation (11).

Primary smoking prevention is perhaps even more important. In New Zealand, publicity about smoking and blindness resulted in increased telephone calls to the national Quitline (9) and a television campaign incorporating the (slightly modified) Australian eye advertisement was considered more successful than other advertisements relating smoking to stroke and heart disease (N Wilson, personal communication, 2003). A sustained public health campaign in the United Kingdom is warranted to increase awareness of the ocular hazards associated with smoking, "North West Action on Smoking and Health" (http://www.nwash.co.uk) has launched a leaflet describing these risks alongside user friendly advice on smoking cessation. The Royal College of
Ophthalmologists supports this initiative. More novel, varied, and specific pack warnings of the impact of smoking on health (10), including eyesight, might help as primary prevention efforts. Warnings targeted at specific concerns may be more effective than current general statements—"Smoking is a major cause of blindness" has been suggested (12). The finding that smokers develop age related macular degeneration around 10 years earlier than non-smokers (5) could also be a potent message in public awareness campaigns.

Tobacco smoking is the prime modifiable risk factor for age related macular degeneration. Evidence indicates that more than a quarter of all cases of
age related macular degeneration with blindness or visual impairment are attributable to current or past exposure to smoking. Patients, health professionals, and the public will benefit from greater awareness of this causal association. Smoking cessation advice should be introduced and evaluated. Similarly, research examining the behaviour of smokers as result of acquired knowledge about smoking and the risk of visual impairment or blindness could usefully inform public health campaigns. Policy initiatives based on these concepts are now clearly needed.

Simon P Kelly, consultant ophthalmic surgeon Bolton Hospitals NHS Trust, Bolton BL4 0JR ( simon.kelly@boltonh-tr.nwest.nhs.uk )

Judith Thornton, honorary research fellow, Georgios Lyratzopoulos, lecturer in public health, Richard Edwards, senior lecturer in public health Evidence for Population Health Unit, School of Epidemiology and Health Sciences, University of Manchester, Manchester M13 9PT

Paul Mitchell, professor of clinical ophthalmology University of Sydney Department of Ophthalmology, Centre for Vision Research, Westmead Hospital, Westmead, NSW 2145, Australia


Additional references (1-10), a table, and methods appear on bmj.com
We are grateful to P McElduff, lecturer in statistics, Evidence for Population Health Unit, University of Manchester for statistical help.

The Retinal Research Endowment Fund, Bolton Hospital NHS Trust supported this work.

Competing interests: RE is the chair (unpaid) of North West Action on Smoking and Health, and the Faculty of Public Health's representative to the Royal College of Physicians Tobacco Group.


Smith W, Assink J, Klein R, Mitchell P, Klaver CCW, Klein BEK, et al. Risk factors for age-related macular degeneration. Pooled findings from three
continents. Ophthalmology 2001;108: 697-704.
Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy. The Blue Mountains eye study. Arch Ophthalmol 1996;114: 1518-23.[Abstract]
Klein R, Klein BEK, Linton KLP, DeMets DL. The Beaver Dam eye study. The relation of age-related maculopathy to smoking. Am J Epidemiol 1993;137:
Vingerling JR, Hofman A, Grobbee DE, de Jong PTVM. Age-related macular degeneration and smoking. The Rotterdam study. Arch Ophthalmol 1996;114:
Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related maculopathy. The Blue Mountains eye study. Arch Ophthalmol
2002;120: 1357-63.
Klein R, Klein BEK, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 1998;147:
Klein R, Klein BEK, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking. The Beaver Dam Eye Study. Am J
Epidemiol 2002;156: 589-98.
Beatty S, Hui-Hiang K, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol
2000;45: 115-34.
Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United
Kingdom? Br J Ophthalmol 2003;87: 312-7.
Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular
Photocoagulation Study Group. Arch Ophthalmol 1986;104: 503-12.
Gordon JS, Andrews JA, Lichtenstein, Severson HH, Akers L, Williams C. Ophthalmologists' and optometrists' attitudes and behaviours regarding tobacco cessation intervention. Tobacco Control 2002;11: 84-5.
Mitchell P, Chapman S, Smith W. Smoking is a major cause of blindness. Med J Aust 1999;171: 173-4.